FibroBiologics Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced an upcoming presentation at the BIO International Convention 2025. The presentation, scheduled for June 17, 2025, will be delivered by the company's Founder and CEO, Pete O'Heeron, in Boston, MA. It will cover recent corporate milestones and research developments utilizing fibroblast-based technology for conditions such as wound healing, multiple sclerosis, and psoriasis. Notably, the company is preparing to initiate a Phase 1/2 clinical trial later this year, focusing on wound healing in diabetic foot ulcers. This trial aims to explore the potential of fibroblast-based therapies to address underlying biological dysfunctions in chronic diseases. Results from this clinical trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.